A trusted and essential partner
to the biopharmaceutical
industry, providing 27 years
of in-depth research, analysis
and data on innovation
and excellence —
from biology to the patient.

Get a Free Trial

4:54 PM Jun 19, 2019
BioCentury  |  Regulation

Why China’s 4 + 7 policy is good news for innovative drug developers

China’s new policy on generic drugs is likely to have knock-on benefits for drug developers aiming to bring innovative compounds to the China market.

Read More
7:03 PM Jun 14, 2019
BioCentury  |  Politics, Policy & Law

Signs of hope on patent eligibility reform as Congress weighs arguments

The wait is still far from over for fixing the rules on what can be patented -- a move that could give diagnostics a fighting chance of becoming commercially viable. That said, a three-day...

Read More
4:45 PM Jun 14, 2019
BioCentury  |  Politics, Policy & Law

No more crickets: The biopharma industry must speak out against the Trump administration’s fetal tissue ban

When President Donald Trump considered a range of options about regulating the use of fetal tissue in medical research, he made a simple political calculation. A ban would solidify support from...

Read More
2:21 PM Jun 14, 2019
BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a...

Read More
2:07 PM Jun 13, 2019
BC Innovations  |  Product Development

Why BioMarin took gene therapy manufacturing into its own hands

As gene therapy companies fight for space at contract manufacturers, BioMarin has leveraged its expertise in biologics to design its own capabilities for manufacturing gene therapies and gain...

Read More
1
2
3
4
5

Browse

{{ item.title }}
Browse all categories